FDA Approves Unknown Drug — INNOGENIX INC
The FDA has approved Monday's Brief filing for INNOGENIX INC, now awaiting data to confirm market status for the generic. This regulatory milestone positions the company for potent…
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
The FDA has approved Monday's Brief filing for INNOGENIX INC, now awaiting data to confirm market status for the generic. This regulatory milestone positions the company for potent…
CMP Pharma, Inc. secured FDA approval on July 29, 2026 for its generic version of QLONILIK (clonidine hydrochloride), marking a significant step toward capturing market share in th…
HIKMA Pharmaceuticals announced on Tuesday that the U.S. FDA approved its Abbreviated New Drug Application (ANDA 218728), signaling a positive pipeline development that positions t…
Somerset Therapeutics has received FDA approval for the intravenous formulation of sugammadex, the antidote to rocuronium bromide, marking a pivotal expansion of its portfolio. Thi…
Hikma Pharmaceuticals USA Inc. announced on Friday the approval of sugammaDEX sodium for the intravenous treatment of hyperkalemia, securing a key FDA ANDA to expand its critical c…
TEVA PHARMS USA INC announced the FDA approval of its ANDA application 214126, clearing the way for the launch of the generic version of the Blockbuster drug. This regulatory miles…
Baxter Healthcare Corporation received marketing authorization for a generic Intramuscular Diazepam solution on July 28, 2026, introducing additional pricing pressure in the Emerge…
MANKIND PHARMA announced FDA approval for ANDA214230 on July 28, 2026, a decision expected to strategically expand its product portfolio and drive revenue growth through increased …
VIATRIS SPECIALTY receives FDA approval for the New Drug Application 219990 on July 28, 2026, with significant market implications expected to drive performance across the specialt…
PAI HOLDINGS announced the approval of its ANDA by the FDA for a new generic drug on July 28, setting the stage for imminent market entry and potential revenue growth as it challen…
Sun Pharmaceutical Industries announced Monday that the FDA has approved the ANDA for sugammadex sodium, expanding a strategic market opportunity within the rapidly growing reversa…
Alembic Pharmaceuticals Inc. received FDA approval for its 6 mg prucalopride succinate tablets (ANDA 219234) on July 27, 2026, reportedly entering the market following a patent exp…
**LUPIN** announced today that it received final approval from the U.S. FDA for a new anda, entering the market for a generic with a specific launch date in July 2026. This authori…
Meitheal Pharmaceuticals Inc. announced Tuesday that the FDA has granted approval for the first generic version of GARZULYS (insulin aspart), a fast-acting subcutaneous product pre…
Further strengthening its diverse portfolio, Japan’s Otsuka Pharmaceutical secured regulatory approval on July 24 for a new treatment, with the authorization poised to broaden the …
FDA granted approval to Kenvue Brands for its brand named $(INSERT_BRAND_NAME)$ on July 24, 2026, which is expected to provide a significant new revenue stream and strengthen the c…
**FDA Approval Granted to Outlook Therapeutics for BLA On July 24, 2026, the FDA granted approval to Outlook Therapeutics for BLA761320, a decision that the company anticipates wil…
Hisun Pharmaceuticals USA, Inc. announced on July 23, 2026, the approval of its Abbreviated New Drug Application for intravenous fludarabine phosphate, aiming to expand accessibili…
Johnson & Johnson Receives FDA De Novo Authorization For Its OTTAVA Robotic Surgical System
BIOCON PHARMA received FDA approval for the ANDA-pending drug on July 22, 2026, which is expected to expand its generic market share and bolster revenue growth. This clearance allo…